Fig. 1: The enhanced expression of NCX1 and TRPC1 in human primary gastric cancer tissues and cells.

Western blot analysis applied to compare the expression levels of NCX1 proteins between gastric cancer (GC) tissues and adjacent normal (Nor) tissues from 52 GC patients: 34 pairs with high expression (A), 13 pairs with low expression (B), and 5 pairs without difference (C). D Summary data showing the percentage of high, low and indifference of NCX1 expression in GC tissues compared to adjacent tissues. E, F Representative and summary data of immunohistological staining on NCX1 proteins in GC tissues compared to adjacent tissues. Scale bar=100 μm for each image. Negative control: without primary antibody. (^****P < 0.0001, n = 80 patients). Relative NCX1 protein levels in GC tissues from the patients with different stages (G), tumor sizes (H), and lymphatic metastasis (I). (^*P < 0.05, n = 80 patients). J Kaplan–Meier analysis of survival ratio of GC patients with low and high NCX1 expression levels (^*P < 0.05, n = 80 patients). K, L Western blot analysis of NCX1 and TRPC1 protein levels in GES1 and GC cell lines. M Immunofluoresence staining images of NCX1 and TRPC1 proteins with primary antibody and without the antibody (negative control) in MKN45, AGS and SGC7901 cells. Scale bar=10 μm for each image. N–Q Co-immunoprecipitation showing the binding of NCX1 and TRPC1 proteins in GC cells.